secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inozyme Pharma, Inc. (—)
CIK:        0001693011
Form:       8-K
Filed at:   2024-10-07T23:59:59+00:00
Accession:  0000950170-24-113241
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Inozyme Pharma appoints Erik Harris as Class II director effective October 3, 2024
--------------------------------------------------------------------------------

- Erik Harris, Chief Commercial Officer and EVP at Ultragenyx, appointed to Inozyme's Board as Class II director.
- Director compensation: $40,000 annual cash retainer, initial option for 56,000 shares (3-year vest), annual option for 28,000 shares.
- Mr. Harris has over 20 years of biopharma commercial experience including roles at InterMune, Genentech, and Bristol-Myers Squibb.
- Standard indemnification agreement entered into; no family relationships or transactions with Inozyme officers require disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1693011/000095017024113241/0000950170-24-113241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1693011/000095017024113241/inzy-20241003.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-113241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer